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Abstract
Objectives: The study focused on the plasma levels of  vitamin B6 and homocysteine in different genotypes of  MTHFR (C677T, 
A1298C) and GABRG2 (C588T, C315T) genes in carbamazepine resistant epilepsy in the population of  Khyber Pakhtunkhwa.
Methodology: Patients who were possible candidates for carbamazepine therapy were followed for six months for their seizure 
control. Plasma levels of  vitamin B6 and homocysteine were determined using immunoassay based techniques at baseline and 
after six months. MTHFR (C677T, A1298C) and GABRG2 (C588T, C315T) genes were genotyped using restriction fragment 
length polymorphisms. Seizure control during therapy was recorded on a standardized proforma.
Results: Low vitamin B6 levels and hyperhomocysteinemia were found in 61.7% of  resistant patients (n=34). Resistant patients 
had the following frequencies of  variant genotypes (677CT=38.1% and 677TT=24.4%; 1298AC=42.2% and 1298CC=26.1%; 
588CT= 47.6% and 315TT= 33.3%) of  MTHFR (C677T and A1298C) and GABRG2 (C588T and C315T) genes. A significant 
decline in vitamin B6 (P<0.0001) and hyperhomocysteinemia were found in variant genotypes of  MTHFR (C677T, A1298C) 
and GABRG2 (C588T, C315T) genes.
Conclusion: Following six months of  carbamazepine of  therapy in heterozygous variant genotypes of  MTHFR (677CT and 
1298AC) and GABRG2 (588CT and 315CT) genes, we observed a significant fall in vitamin B6 levels and hyperhomocysteinemia. 
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Introduction
Epilepsy is a neurological disorder manifested by repeat-
ed, unprovoked seizures that affects one percent of  the 
population globally1. Different factors are responsible for 
resistant epilepy, and these need to be explored2. Genet-
ic factors and nutrition are considered one of  the main 
causes of  resistant epilepsy3,4. Nutrients that reduce sei-
zure frequencies include vitamin B6, magnesium, vitamin 
E, manganese, taurine, dimethylglycine and omega-3 fatty 
acids5. Moreover, vitamin B6 plays an important role in 
the development and differentiation of  central nervous 
system (CNS)6. Deficiency of  vitamin B6 level leads  to 
decrease in synthesis of  GABA, which is an inhibitory 
neurotransmitter in CNS7,8. Low GABA is also associat-
ed with CNS  disorders such as epilepsy, anxiety and de-
pression9. On the other hand, methylenetetrahydrofolate 
reductase (MTHFR) plays an important role in folate and 
homocysteine metabolism10. Reports say that MTHFR 
(C677T and A1298C) gene polymorphism is associated 
with elevated levels of  homocysteine. Moreover, deficien-
cy of  vitamin B6, B12, and folic acid is also responsible 
for hyperhomocysteinemia7,8. There is a reports about 
the association of  C677T and A1298C of  MTHFR gene 
polymorphisms with elevated  levels of  homocysteine 
due to vitamin B6, vitamin B12 and folic acid deficiency 
in patients with myocardial infarction in Pakistani pop-
ulation11. However, as vitamin B6 helps in synthesis of  
GABA, an inhibitory neurotransmitter and whereas there 
are no reports for levels of  vitamin B6 in epileptics treat-
ed with carbamazepine, hence, the current study was de-
signed to know about the levels of  vitamin B6 and homo-
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cysteine in epileptic patients treated with carbamazepine. 
The study also focused to know the variant of  MTHFR 
and GABRG2 genes frequently experiencing vitamin B6 
deficiency with ultimate poor seizure control.
Materials and methods
Epileptic patients
The study was approved by the Ethical Board of  Khy-
ber Medical University, Peshawar via approval no: DIR/
KMU-EB/AC/000047. Seventy nine patients suffering 
from different types of  epilepsy who were to be treat-
ed with carbamazepine were selected at out-patient De-
partment of  Neurology of  Government Lady Reading 
Hospital, Peshawar, Pakistan.  Medical history, careful 
physical examination and complete investigations were 
performed by respective ward/OPD neurologists at time 
of  enrollment into the study. All patients signed written 
consent after an explaination of  the steps and aims of  the 
study in the context of  their local language (s).
Study design and protocol
It was a hospital based longitudinal study. Patients who 
received carbamazepine as monotherapy were enrolled in 
the study. Baseline interviews were carried out for selec-
tion, evaluation of  seizures on the initiation of  the ther-
apy. Patients were asked to visit the epilepsy out-patient 
Department of  Neurology on monthly basis for seizure 
control. Patients with epilepsy were then evaluated in the 
sixth month of  the therapy for possible shift in their plas-
ma levels of  vitamin B6 as well as their clinical screening 
for better epilepsy management.
Collection of  blood and sampling techniques
Patients were purposively enrolled in the study. Blood 
samples were collected at baseline and in the 6th month of  
the therapy. The blood was taken in gel tubes following 
administration of  the drug in the morning. The plasma 
was separated and subjected to biochemical analysis for 
levels of  vitamin B6 and homocysteine. For genotyping 
blood samples were taken in EDTA tubes which were 
subjected for DNA extraction and genotyping.
Genotyping of  MTHFR and GABRG2 Genes
Genomic DNA was extracted using kit method (Nu-
cleoSpin® Blood, Germany).  Briefly describing, the 
extraction of  DNA was carried out through series of  
reactions which included deproteination of  blood (pro-
teinase K), lysis of  blood cells (lysis buffer), purification 
of  DNA (washing buffer), and finally elution of   DNA 
(through elution buffer) according to standard protocols 
provided by respective manufacturers. The extracted 
DNA was stored on -20 °C for further analysis. MTH-
FR (C677T and A1298C) and GABRG2 (C588T and 
C315T) genes were amplified using gradient thermo cy-
cler. After amplification, the PCR products were run on 
2% agarose gel and assessed their size with 50Pb ladder. 
MTHFR (C677T) gene was amplified by using primers 
5-TTTGAGGCTGACCTGAAGCACTTGAAGGAG-3 
and 5-GAGTGGTAGCCCTGGATGGGAAAGATC-
CCG-3. The amplified product was digested using re-
striction enzyme Hinf  I.  Similarly, MTHFR (A1298C) 
gene was amplified by using primers 5-CTTTGGGGA 
GCTGAA GGACTACTAC-3 and 5-CACTTTGTG AC-
CATTCCGGTTTG-3.The resulted product was digested 
using restriction enzyme MboII. GABRG2 (C588T) gene 
was amplified by using primers 5- AATCACCTTTTAT-
TCTAATGGTC-3 and 5-CAGTGAAGGCAACT-
TACTAAGA-3. The amplified product was digested 
using restriction enzyme ApoI.  GABRG2 (C315T) 
gene was amplified using primers 5-CAAATGTGGT-
GAATTAGTAACTGG-3 and 5- TCACATTTTCTCT-
CAAACATGC-3. The PCR product was digested using 
restriction enzyme BasMI. The digested products of  all 
amplified exons were run on 5% agarose gel and respec-
tive fragment sizes were assessed with 50Pb ladder.
Analysis of  plasma levels of  vitamin B6
Vitamin B6 levels were determined using immunoassay 
based Kit (Alpha Diagnostic International USA). Serial 
dilutions of  standard solutions and samples were added 
into 96 wells using ELISA vitamin B6 plate. The plate 
was incubated for 1 hour at 37 °C. Biotinylated detection 
antibody working solution (1X) was added into each well 
and incubated again for 45 minutes at 37 °C. The plate 
was washed 3 times after incubation. HRP conjugate an-
tibodies (1X) were added into each well. Mixed gently and 
incubated for 30 minutes at 37 °C. The plate was washed 
5 times. Finally, we added TMB substrate into each well. 
Mixed gently and incubated the plate for 15 minutes again 
at 37 °C. Reaction stop solution was added to all wells. 
Absorbances of  wells were read at 450 nm using micro 
plate reader.
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Analysis of  plasma levels of  homocysteine
Homocysteine levels were also determined using enzyme 
linked Immunosorbant assay (ELISA) (Kit Abbott Labo-
ratories Ltd; Pakistan) technique. Standard serial dilutions, 
primary, secondary antibody dilutions and buffer were 
prepared according to the manufacturers’ procedures. Se-
rial dilutions of  standard and samples were added into a 
96 well plate. The plate was incubated for 2 hours at 37 
°C. Then added Biotin-antibody (1X) was added into each 
well of  the plate following proper washing and again was 
added incubated for 1 hour at 37 °C.  Then a HRP-avidin 
(1X) to each well and again incubated for 1 hour at 37 °C. 
The plate was washed 5 times and TMB substrate was 
added to each well. The plate was incubated again for 30 
minutes at 37 °C. Finally, 50 µl of  reaction stop solution 
was added to each well and the absorbance of  plate on 
450 nm.
Measurement of  seizure control
Seizure control was recorded in the form of  reduction 
of  frequencies or duration of  seizures on a standardized 
proforma in the context of  their local language (s).
Statistical analysis
Changes in plasma levels of  vitamin B6 and homocys-
teine between baseline and end time of  the study were 
compared using student “t” test. Resistant seizures were 
expressed in their frequencies and percentages on a 
Graphpad Prism. The data was analyzed using a Graph-
pad Prism 6 at 95% CI, P ≤ 0.05.
Results
Demographic characteristics of  epileptic patients
Patients’ demographic data and types of  seizures are ex-
pressed in Table 1. It is evident from Table 1 that mean age 
of  both male and female patients were uniform (P>0.05). 
Generalized tonic clonic seizures were most prevalent 
(69.6 %) at time of  incorporation into the study. 17 pa-
tients were dropped from the study because they either 
did not report to the epilepsy care clinic or lacked interest 
in the study.
Plasma levels of  Vitamin B6 in different genotypes of  
MTHFR (C677T, A1298C) and GABRG2 (C588T, 
C315T) genes polymorphisms
Vitamin B6 plasma levels were significantly (P<0.05) low 
at end study as compared to base line (Table 2). Fall in 
mean levels of  vitamin B6 was also significant (P<0.0001) 
in homozygous and heterozygous variant genotypes of  
the target genes except for heterozygous variant of  GA-
BRG2 (588CT). However, upon comparision with refer-
ence values (30-150 mmole/L) of  vitamin B6, it is evi-
dent that GABRG2 (C588T, C315T) and all its variants 
had vitamin B6 levels of  the lower limit of  the reference 
range, despite of  a statistical significant fall in their levels 
(Table 2).
Table 1: Demographic data and types of epileptic patients 
Demographic data Patients (n=79) on Baseline Patient (n=62) on 6th months 
Age (year) , mean ± SD (range) 18.1±8.2 (1-42) 18.08±7.5 (1-42) 
Male, n (%) 37 (47 ) 28 (45.2) 
Female, n (%) 42 (53) 34 (54.8) 
Generalized Tonic Clonic Seizure, n (%) 50 (70.9) 44 (77.4) 
Generalized Tonic Seizure, n (%) 4 (5.1) 1 (1.6) 
Atonic Seizure, n (%) 3 (3.8) 2 (3.2) 
Simple Partial Seizure, n (%) 3 (3.8) 3 (4.8) 
Complex Partial Seizure, n (%) 5 (6.3) 3 (4.8) 
Secondary Generalized Complex Seizure, n (%) 12 (7.6) 6 (9.7) 
Dose (mg/day), mean ± SD (range) 455±133 (200-800) 495±133 (200-800) 
                            
                          Word AEDs used in the discussion mean antiepileptic drugs, while KP means Khyber Pakhtunkhwa 
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Mean plasma levels of  homocysteine in different 
Genotypes of  MTHFR (C677T, A1298C) and GA-
BRG2 (C588T, C315T) Genes Polymorphisms
Rise in mean plasma levels of  homocysteine at six months 
was not statistically significant (P>0.05) as compared to 
their baseline (Table 3) values. Though, there was a sig-
nificant difference in vitamin B6 levels in respective ho-
mozygous and heterozygous variants of  the target genes.
Table 3: Plasma levels of homocysteine in variants of MTHFR (C677T, A1298C) and 
GABRG2 (C588T, C315T) genes polymorphisms of epileptics treated 
with carbamazepine therapy 
 
Gene Genotypes Homocysteine plasma level (mmole/L), 





P values † 
MTHFR C677T CC (n=32, 27) 6.7±2.3 7.2±2.0 0.20 
CT (n=29, 22) 9.8±3.2 10.1±3.9 0.83 
TT (n=18, 13) 10.6±3.4 11.2±2.7 0.75 
MTHFR A1298C AA (n=35, 28) 7.3±2.8 7.7±2.6 0.42 
AC (n=29, 22) 9.0±2.5   11.3±2.8 0.07 
CC (n=15, 12) 9.1±4.5 8.7±4.0 0.88 
GABRG2 C588T CC (n=37, 30) 7.9±3.0 8.5±3.0 0.37 
CT (n=27, 21) 6.8±2.6 7.2±1.9 0.75 
TT (n=15, 11) 8.2±2.8 10.7±3.1 0.09 
GABRG2 C315T CC (n=36, 32) 7.8±3.2 8.5±3.0 0.28 
CT (n=25, 16) 7.3±2.2 7.9±2.7 0.52 
TT (n=18, 14) 8.0±3.8 
  8.2±3.6    0.91 
   
          †= T test, Mean level of homocysteine on baseline verses mean levels of homocysteine on sixth month of 
carbamazepine therapy 
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Table 2: Plasma levels of vitamin B6 in variants of MTHFR (C677T, A1298C) 
and GABRG2 (C588T, C315T) genes polymorphisms of 
epileptics treated with carbamazepine therapy 
 






P values † 
           
MTHFR 
C677T 
CC (n=32, 27) 71.9±20.8 45.2±22.3 
  
< 0.0001*** 
CT (n=29, 22) 67.2±20.7 31.0±22.8 0.0001*** 
TT (n=18, 13) 62.0±18.0 27.3±7.3 0.0001*** 
MTHFR 
A1298C 
AA (n=35, 28) 71.2±19.2 45.9±22.4 < 0.0001*** 
AC (n=29, 22) 65.1±24.9 20.4±6.6 < 0.0001*** 
CC (n=15, 12) 64.3±23.4 23.3±4.9 0.0005*** 
GABRG2 
C588T 
CC (n=37, 30) 68.9±20.4 39.4±20.4 < 0.0001*** 
CT (n=27, 21) 71.8±25.8 49.4±25.3 0.08 
TT (n=15, 11) 71.3±16.8 31.9±27.7 0.002** 
GABRG2 
C315T 
CC (n=36, 32) 49.4±21.9 39.8±20.8 < 0.0001*** 
CT (n=25, 16) 70.5±17.4 41.4±31.2 0.01* 
TT (n=18, 14) 69.1±18.0 37.0±20.9 0.003** 
  
          †= T test, Mean level of vitamin B6 on baseline verses mean levels of vitamin B6 on sixth month  
         of carbamazepine therapy 
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Seizure control
There were 34 patients resistant to carbamazepine thera-
py (Table 4). Vitamin B6 levels were below the reference 
range (30-150 mmole/L) in 21 resistant patients. MTH-
FR (C677T, A1298C) observed high frequency (42.2%) 
with low plasma levels of  vitamin B6 in patients that had 
poor seizure control (Table 4).
Discussion
Seizure control with carbamazepine is affected by differ-
ent factors. However, gene polymorphisms and nutrition 
are also considered as contributing factors in resistant ep-
ilepsy. We observed that plasma levels of  vitamin B6 were 
low offer six months of  the therapy once we compared 
with their baseline levels. As mentioned earlier, some of  
the variants, particularly heterozygous variant of  MTHFR 
(C677T, A1298C) and GABRG2 (C588T, C315T) genes 
were relatively more resistant to their respective homozy-
gous variants. Other studies suggest that vitamin B6 levels 
can be affected by various factors like carbamazepine and 
some anti-tuberculous drugs6.  Recent studies have shown 
that duration of  antiepileptic drugs (AEDs) is also signifi-
cantly associated with low plasma levels of  vitamin B6 and 
elevated levels of   homocysteine12. Hence, our findings 
suggest that hyperhomocysteinemia is mostly prevalent in 
heterozygous variant genotypes of  MTHFR (C677T and 
A1298C) gene which appear in the 6th month of  the car-
bamazepine therapy. An interesting part of  the study was 
that resistant patients to carbamazepine therapy had low 
level of  vitamin B6, despite their mean plasma level of  
carbamazepine was within therapeutic range (4-12 mg/L 
in the resistant patients (data not shown) this suggests 
possible changes at drug receptors sites or poor affini-
ty for receptors, which still need to be discovered using 
modern techniques. Thus we agree with Ebid et al.13 who 
reported that therapeutic steady state did not guarantee 
effective clinical response13. The resistance in response 
may be due to MTHFR (C677T and A1298C) gene poly-
morphisms that may alter the individual response to a 
drug despite having patients’ plasma levels in therapeu-
tic range. As MTHFR gene polymorphisms affect DNA 
methylation leading to differential gene expression that 
can influence the drug response, hence, poor response 
may be attributed to low level of  vitamin B6 as well
14-18. 
On the other hand, vitamin B6 is responsible for synthesis 
of  GABA which  regulates the functions of  alpha, beta 
and gamma subunits of  GABA receptors19. Therefore, 
alteration in receptor site changes its sensitivity to admin-
istered antiepileptic drugs (AEDs) despite plasma levels 
of  AEDs falling within the therapeutic range. The above 
mentioned facts supported the evidence that genetic vari-
ations in genes has a role in multidrug resistance. Howev-
er, heterozygous variants of  MTHFR (C677T, A1298C) 
and GABRG2 (C588T, C315T) genes are more resistant 
to carbamazepine therapy as compared to wild genotypes 
in the population of  Khyber Pakhtunkhwa (KP).
Table 4: Frequencies of different genotypes who were resistant to carbamazepine  
therapy with their respective plasma vitamin B6 and plasma  
homocysteine levels on sixth month of the therapy 
 
Genes Genotypes Genotypes in poor seizure 
control (n=34),n (%) 
Genotypes in low B6 




 (mmole/L) ‡ 
MTHFR 
(C677T) 
            
CC 9 (26.5) 6 (28.6) 22.6±6.7 8.1±2.6 
CT 15 (44.1) 8 (38.1) 20.8±6.4 10.7±3.7 




AA 11 (32.4) 8 (38.1) 23.8±6.2 9.0±3.2 
AC 14 (41.2) 9 (42.8) 20.4±6.6 11.3±2.7 
CC 9 (26.4) 4 (19.1)            23.2±4.9 8.9±4.0 
GABRG2 
(C588T) 
CC 12 (35.3) 8 (38.1) 22.9±5.8 9.7±3.2 
CT 16 (47.1) 10 (47.6) 21.6±1.7 8.6±2.7 
TT 6 (17.6)            3 (14.3) 22.5±8.0 9.1±4.1 
GABRG2 
(C315T) 
CC 12 (35.3) 10 (47.6) 23.0±5.9 10.0±3.9 
CT 13 (38.2) 7 (33.3)            24.2±5.7 7.3±2.1 
TT 9 (26.5) 4 (19.1) 18.8±8.1 11.5±4.4 
†= 30-150 mmole/L, ‡= 4-9 mmole/L 
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Conclusion
Following six months of  carbamazepine therapy in re-
sistant epilepy, we observed a significant fall in vitamin 
B6 level in heterozygous variant genotypes of  MTHFR 
(677CT and 1298AC) and GABRG2 (588CT and 315CT) 
genes. Conversely, their plasma homocysteine levels start-
ed rising in the 6th month of  the carbamazepine therapy 
in resistant heterozygous variants.
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